JNJ

238.49

-0.19%↓

UNH

278.06

+0.21%↑

TMO

543.22

+0.16%↑

ABT

111.92

+1.02%↑

ISRG

497.52

+0.89%↑

JNJ

238.49

-0.19%↓

UNH

278.06

+0.21%↑

TMO

543.22

+0.16%↑

ABT

111.92

+1.02%↑

ISRG

497.52

+0.89%↑

JNJ

238.49

-0.19%↓

UNH

278.06

+0.21%↑

TMO

543.22

+0.16%↑

ABT

111.92

+1.02%↑

ISRG

497.52

+0.89%↑

JNJ

238.49

-0.19%↓

UNH

278.06

+0.21%↑

TMO

543.22

+0.16%↑

ABT

111.92

+1.02%↑

ISRG

497.52

+0.89%↑

JNJ

238.49

-0.19%↓

UNH

278.06

+0.21%↑

TMO

543.22

+0.16%↑

ABT

111.92

+1.02%↑

ISRG

497.52

+0.89%↑

Search

Stevanato Group SpA

Abrir

SetorSaúde

15.74 -2.18

Visão Geral

Variação de preço das ações

24h

Atual

Mín

15.56

Máximo

16.5

Indicadores-chave

By Trading Economics

Rendimento

10M

49M

Vendas

23M

303M

P/E

Médio do Setor

26.217

84.243

EPS

0.162

Rendimento de Dividendos

0.35

Margem de lucro

16.205

Funcionários

5,521

EBITDA

10M

73M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+74.19% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

0.35%

2.28%

Próximos Ganhos

5 de mar. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-2.4B

4.3B

Abertura anterior

17.92

Fecho anterior

15.74

Sentimento de Notícias

By Acuity

50%

50%

144 / 352 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Stevanato Group SpA Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

9 de fev. de 2026, 17:25 UTC

Aquisições, Fusões, Aquisições de Empresas

Eli Lilly to Buy Biotech Orna Therapeutics for Up to $2.4 Billion -- Update

9 de fev. de 2026, 23:46 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for Domestic Policy Measures -- Market Talk

9 de fev. de 2026, 23:43 UTC

Conversa de Mercado

Gold Falls on Possible Technical Correction -- Market Talk

9 de fev. de 2026, 23:14 UTC

Conversa de Mercado

WiseTech's Bull Reckons AI-Driven Selloff Is Overdone -- Market Talk

9 de fev. de 2026, 22:29 UTC

Conversa de Mercado

Australian Coking Coal Price Seen Falling Once Supply Disruptions Ease -- Market Talk

9 de fev. de 2026, 22:19 UTC

Conversa de Mercado

Pro Medicus's Business Case Made More Compelling by AI Adoption -- Market Talk

9 de fev. de 2026, 22:08 UTC

Conversa de Mercado

Minerals 260 Bull Bets on Production Scale, Takeover Appeal -- Market Talk

9 de fev. de 2026, 22:01 UTC

Ganhos

Friedman Industries Sees 4Q Sales Volume to Generally Consistent With 3Q, With Sequential Improvement in Sales Margins

9 de fev. de 2026, 21:59 UTC

Ganhos

Friedman Industries: Hedging Activities Continued to Perform as Anticipated by Mitigating Impact of Commodity Price Volatility

9 de fev. de 2026, 21:59 UTC

Ganhos

Friedman Industries: Average Selling Prices Began to Improve as Quarter Progressed

9 de fev. de 2026, 21:58 UTC

Ganhos

Friedman Industries 3Q Sales $168M >FRD

9 de fev. de 2026, 21:50 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Financial Services Roundup: Market Talk

9 de fev. de 2026, 21:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

9 de fev. de 2026, 21:48 UTC

Ganhos

Friedman Industries 3Q EPS 43c >FRD

9 de fev. de 2026, 21:17 UTC

Ganhos

Kyndryl Stock Drops 55%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

9 de fev. de 2026, 21:13 UTC

Conversa de Mercado

U.S. Ethanol Crush Margins Near Break-Even -- Market Talk

9 de fev. de 2026, 21:04 UTC

Ganhos

Retail Sales Data Should Confirm a Robust Holiday Season -- Barrons.com

9 de fev. de 2026, 20:30 UTC

Conversa de Mercado

Oil Futures Gain As U.S.-Iran Risk Premium Holds -- Market Talk

9 de fev. de 2026, 20:02 UTC

Conversa de Mercado

U.S. Natural Gas Falls on Warmer Weather Outlook -- Market Talk

9 de fev. de 2026, 19:42 UTC

Conversa de Mercado

Japan's Yield Curve Expected to Flatten -- Market Talk

9 de fev. de 2026, 19:31 UTC

Conversa de Mercado

Nike Seen Regaining Relevance With Consumers -- Market Talk

9 de fev. de 2026, 19:27 UTC

Conversa de Mercado

Gold Climbs Back Over $5,000/oz -- Market Talk

9 de fev. de 2026, 19:05 UTC

Conversa de Mercado

Nike Returns to List of Hottest Brands -- Market Talk

9 de fev. de 2026, 18:19 UTC

Conversa de Mercado

Lower Dollar Doesn't Translate to Boost in Grains -- Market Talk

9 de fev. de 2026, 17:41 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, AppLovin, Monday.com, Valaris, and More -- Barrons.com

9 de fev. de 2026, 17:31 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, Monday.com, Valaris, Cleveland-Cliffs, and More -- Barrons.com

9 de fev. de 2026, 17:20 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Financial Services Roundup: Market Talk

9 de fev. de 2026, 17:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

9 de fev. de 2026, 17:17 UTC

Conversa de Mercado

Century Aluminum Announces Next Steps of Okla. Project -- Market Talk

9 de fev. de 2026, 17:16 UTC

Ganhos

Kyndryl Stock Drops 56%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

Comparação entre Pares

Variação de preço

Stevanato Group SpA Previsão

Preço-alvo

By TipRanks

74.19% parte superior

Previsão para 12 meses

Média 27 USD  74.19%

Máximo 30 USD

Mínimo 24 USD

Com base em 3 analistas de Wall Street que oferecem metas de preço de 12 meses para Stevanato Group SpA - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

3 ratings

2

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

21.56 / 22.61Suporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Weak Bearish Evidence

Longo Prazo

Bullish Evidence

Sentimento

By Acuity

144 / 352 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Stevanato Group SpA

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
help-icon Live chat